Ferguson, Gary T. http://orcid.org/0000-0002-3277-4110
Maltais, François
Karpel, Jill
Bothner, Ulrich http://orcid.org/0000-0001-6515-0841
Kloer, Isabel
Trampisch, Matthias
Buhl, Roland
Funding for this research was provided by:
Boehringer Ingelheim (N/A, N/A, N/A, N/A, N/A, N/A, N/A)
Article History
Received: 14 July 2020
Accepted: 3 November 2020
First Online: 4 December 2020
Competing interests
: G.T.F. has received grants, personal fees, and non-financial support from Boehringer Ingelheim, Novartis, AstraZeneca, Pearl Therapeutics, and Sunovion; grants and personal fees from Theravance; and personal fees from Verona, Mylan, Innoviva, GlaxoSmithKline, and Circassia outside the submitted work. F.M. received fees for speaking at conferences sponsored by Boehringer Ingelheim, Novartis, and Grifols; research grants for participating in multicenter trials sponsored by GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Novartis; and unrestricted research grants from Boehringer Ingelheim, Novartis, and Grifols. He also holds a CIHR/GlaxoSmithKline research chair on COPD. J.K. has nothing to disclose. U.B., I.K., and M.T. are employees of Boehringer Ingelheim. R.B. has received grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche; and personal fees from AstraZeneca, Chiesi, Cipla, and Teva. The authors received no compensation related to the development of the manuscript.